LUC00323I2 - - Google Patents

Info

Publication number
LUC00323I2
LUC00323I2 LU00323C LUC00323C LUC00323I2 LU C00323 I2 LUC00323 I2 LU C00323I2 LU 00323 C LU00323 C LU 00323C LU C00323 C LUC00323 C LU C00323C LU C00323 I2 LUC00323 I2 LU C00323I2
Authority
LU
Luxembourg
Application number
LU00323C
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of LUC00323I2 publication Critical patent/LUC00323I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nuclear Medicine (AREA)
LU00323C 2008-08-01 2023-12-01 LUC00323I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8546208P 2008-08-01 2008-08-01
US11179108P 2008-11-06 2008-11-06

Publications (1)

Publication Number Publication Date
LUC00323I2 true LUC00323I2 (fr) 2026-02-02

Family

ID=41610978

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00323C LUC00323I2 (fr) 2008-08-01 2023-12-01

Country Status (25)

Country Link
US (7) US8778305B2 (fr)
EP (3) EP3222615B1 (fr)
JP (6) JP5588441B2 (fr)
KR (1) KR101664855B1 (fr)
CN (3) CN107382846B (fr)
AU (1) AU2009276423B2 (fr)
CA (2) CA2732632C (fr)
CY (3) CY1119367T1 (fr)
DK (2) DK3222615T3 (fr)
ES (2) ES2914593T3 (fr)
FI (1) FIC20230033I1 (fr)
FR (1) FR23C1044I2 (fr)
HK (1) HK1247197A1 (fr)
HR (2) HRP20220742T1 (fr)
HU (3) HUE059436T2 (fr)
LT (3) LT2318366T (fr)
LU (1) LUC00323I2 (fr)
NL (1) NL301250I2 (fr)
NO (1) NO2024006I1 (fr)
PL (2) PL3222615T3 (fr)
PT (2) PT2318366T (fr)
RU (1) RU2494096C2 (fr)
SI (2) SI2318366T1 (fr)
SM (1) SMT201700371T1 (fr)
WO (1) WO2010014933A2 (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
WO2009084995A1 (fr) 2007-12-28 2009-07-09 Exini Diagnostics Ab Système de détection de métastases du cancer des os
PT2318366T (pt) * 2008-08-01 2017-08-02 Univ Johns Hopkins Agentes de ligação a psma e suas utilizações
EP2433322A4 (fr) 2009-05-19 2015-11-04 East Penn Mfg Co Collecteur de courant composite et procédés apparentés
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2013028664A1 (fr) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Agents d'imagerie du psma
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
ES2729555T3 (es) * 2011-11-30 2019-11-04 Univ Johns Hopkins Inhibidores homomultivalentes y heteromultivalentes de antígeno de membrana específico de próstata (PMSA) y usos de los mismos
US20140065070A1 (en) * 2012-08-28 2014-03-06 Mcmaster University Methods of preparing triazole-containing radioiodinated compounds
EA201590783A1 (ru) * 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
PL2970345T3 (pl) * 2013-03-15 2019-12-31 Cancer Targeted Technology Llc Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA
US10232058B2 (en) 2013-10-14 2019-03-19 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
EP3456700A1 (fr) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
JP6292568B2 (ja) * 2013-11-06 2018-03-14 国立大学法人京都大学 ウレア誘導体化合物、これを含有する放射性医薬
EP3533473A3 (fr) 2013-11-14 2019-12-18 Endocyte, Inc. Composés pour la tomographie par émission de positrons
US9713649B2 (en) 2014-01-24 2017-07-25 The Cleveland Clinic Foundation PSMA-targeting imaging agents
US10556916B2 (en) * 2014-04-01 2020-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography
EP2993171A1 (fr) * 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé pour la production des traceurs PET spécifique PSMA
EP3183236B1 (fr) 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Procédé de production d'esters actifs marqués au 18f et leur application illustrée par la préparation d'un traceur pour pet spécifique de l'antigène membranaire spécifique de la prostate (psma)
EP3209336B1 (fr) * 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum Inhibiteurs marqués 18f de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EP3011976A1 (fr) * 2014-10-20 2016-04-27 Deutsches Krebsforschungszentrum Inhibiteurs marqués 18F de l'antigène membranaire spécifique de la prostate (PSMA), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
WO2016065142A2 (fr) 2014-10-22 2016-04-28 The Johns Hopkins University Nouveaux échafaudages et intermédiaires multifonctionnels pour l'imagerie de et le traitement du cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016112382A2 (fr) * 2015-01-09 2016-07-14 The Johns Hopkins University Administration intranasale d'inhibiteurs de glutamate carboxypeptidase (gcp-ii)
US10869940B2 (en) 2015-06-12 2020-12-22 The Board Of Trustees Of The Leland Stanford Junior University Targeted photoacoustic compounds, formulations, and uses thereof
EP3337520A1 (fr) * 2015-08-20 2018-06-27 Universität zu Köln Suivi de douleur par imagerie pet (capture de couleur)
KR102233726B1 (ko) 2015-09-30 2021-03-31 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
US20200231614A1 (en) * 2015-10-22 2020-07-23 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy
KR101639599B1 (ko) 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
EP3400229B1 (fr) 2016-01-10 2024-03-06 Provincial Health Services Authority Composés marqués au 18/19f qui ciblent l'antigène membranaire spécifique de la prostate
DK3481804T3 (da) * 2016-06-10 2025-01-13 Univ Johns Hopkins Forbedret syntese af radioaktivt mærket hæmmer af prostataspecifikt membranantigen (PSMA) [18F]DCFPyL
CN109843339B (zh) * 2016-06-23 2023-07-07 康奈尔大学 影响肿瘤杀伤的双重靶向构建体
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
AU2017348111B2 (en) 2016-10-27 2023-04-06 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
JP6999960B2 (ja) * 2016-11-17 2022-01-19 思路迪（北京）医薬科技有限公司 抗がん作用を有する化合物およびその製造方法ならびにその使用
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung
EP3609541A4 (fr) 2017-04-05 2021-04-07 Cornell University Constructions trifonctionnelles avec pharmacocinétiques réglables utiles dans les thérapies d'imagerie et antitumorales
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
WO2018204477A1 (fr) 2017-05-02 2018-11-08 Cornell University Procédés et réactifs pour ciblage de tumeur avec une efficacité améliorée et une toxicité réduite
WO2018236115A1 (fr) 2017-06-19 2018-12-27 (주)퓨쳐켐 Composé marqué au 18f pour le diagnostic du cancer de la prostate et son utilisation
DK3643707T3 (da) 2017-06-19 2022-05-09 Futurechem Co Ltd 18f-mærket forbindelse til diagnosticering af prostatkræft, og anvendelse deraf
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
BR112020011727A2 (pt) * 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
US10973486B2 (en) 2018-01-08 2021-04-13 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
US12602772B2 (en) 2018-01-08 2026-04-14 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
ES3026214T3 (en) 2018-01-08 2025-06-10 Progenics Pharm Inc System and method for rapid neural network-based image segmentation
US11813340B2 (en) 2018-02-06 2023-11-14 The Johns Hopkins University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
WO2019183633A1 (fr) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Composés conjugués ciblés sur le psma et leurs utilisations
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN109160899B (zh) * 2018-05-16 2021-06-04 上海如絮生物科技有限公司 一种亲水性吡啶类化合物、中间体、其制备方法及应用
CN109160896B (zh) * 2018-05-16 2021-06-25 上海如絮生物科技有限公司 一种亲水性吡啶类化合物中间体及其制备方法
CN109160898B (zh) * 2018-05-16 2021-06-04 上海如絮生物科技有限公司 一种亲水性吡啶类化合物中间体及其制备方法
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
WO2020077259A1 (fr) 2018-10-11 2020-04-16 Progenics Pharmaceuticals, Inc Polythérapie pour le traitement du cancer de la prostate métastatique
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
WO2020139012A1 (fr) 2018-12-27 2020-07-02 (주)퓨쳐켐 Composé ciblant psma introduit par acide carboxylique et utilisation associée
EP4597424A3 (fr) 2019-01-07 2025-10-29 Exini Diagnostics AB Systèmes et procédés de segmentation d'image de corps entier agnostique de plateforme
PL239934B1 (pl) 2019-04-12 2022-01-31 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
AU2020257786B2 (en) 2019-04-17 2025-10-23 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
JP7539921B2 (ja) 2019-04-24 2024-08-26 プロジェニクス ファーマシューティカルズ， インコーポレイテッド 核医学画像における強度ウィンドウ処理の双方向調節のためのシステムおよび方法
BR112021021011A2 (pt) 2019-04-24 2021-12-14 Exini Diagnostics Ab Sistemas e métodos para análise automatizada e interativa de imagens de varredura óssea para detecção de metástases
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
BR112021025810A2 (pt) 2019-06-21 2022-05-10 Provincial Health Services Authority Compostos radiomarcados direcionando o antígeno de membrana específico da próstata
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
AU2020336190A1 (en) * 2019-08-30 2022-03-24 Memorial Sloan Kettering Cancer Center Novel theranostic agents for PSMA positive cancers
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11564621B2 (en) 2019-09-27 2023-01-31 Progenies Pharmacenticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11544407B1 (en) 2019-09-27 2023-01-03 Progenics Pharmaceuticals, Inc. Systems and methods for secure cloud-based medical image upload and processing
KR102269315B1 (ko) 2019-10-24 2021-06-24 서울대학교산학협력단 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물
US11321844B2 (en) 2020-04-23 2022-05-03 Exini Diagnostics Ab Systems and methods for deep-learning-based segmentation of composite images
US11386988B2 (en) 2020-04-23 2022-07-12 Exini Diagnostics Ab Systems and methods for deep-learning-based segmentation of composite images
CN111548305B (zh) * 2020-05-12 2021-08-31 北京师范大学 一种可用于靶向psma的喹啉类化合物及其制备方法
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
CA3163190A1 (fr) 2020-07-06 2022-01-13 Exini Diagnostics Ab Systemes et procedes d'analyse d'image basee sur l'intelligence artificielle pour la detection et la caracterisation de lesions
EP4244216A1 (fr) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands de l'antigène membranaire spécifique de la prostate (psma) contenant des blocs de construction de lieur hétéroaromatiques
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
KR20240072996A (ko) 2021-07-30 2024-05-24 오사카 유니버시티 방사성 표지된 화합물 및 이의 용도
CA3231578A1 (fr) 2021-10-08 2023-04-13 Exini Diagnostics Ab Systemes et procedes d'identification et de classification automatisees de lesions dans des ganglions lymphatiques locaux et des metastases distantes
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CA3256961A1 (fr) 2022-06-08 2023-12-14 Progenics Pharmaceuticals, Inc. Systèmes et méthodes d'évaluation de la charge et de la progression d'une maladie
KR20250130683A (ko) 2023-01-10 2025-09-02 썬 파마 어드밴스트 리서치 컴패니 리미티드 리간드-약물 접합체
US20240285248A1 (en) 2023-02-13 2024-08-29 Progenics Pharmaceuticals, Inc. Systems and methods for predicting biochemical progression free survival in prostate cancer patients
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
US20240354940A1 (en) 2023-04-07 2024-10-24 Progenics Pharmaceuticals, Inc. Systems and methods for facilitating lesion inspection and analysis
WO2025072177A1 (fr) 2023-09-25 2025-04-03 Progenics Pharmaceuticals, Inc. Systèmes et procédés de classification et de prédiction de risque de cancer automatisées
WO2025090594A1 (fr) * 2023-10-25 2025-05-01 The Johns Hopkins University Apprentissage par transfert profond pour la quantification entièrement automatisée de tumeurs et le pronostic de cancer sur pet/ct
DE102023133281B8 (de) * 2023-11-28 2025-07-24 Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien Gmbh Radiotracer und Präkursoren für diese Radiotracer sowie Verwendung dieser Radiotracer als Diagnostika und Therapeutika
CN117670883B (zh) * 2024-01-31 2024-05-07 中国医学科学院北京协和医院 一种鉴别高低级别膀胱癌的方法、设备和系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2233269C2 (ru) * 1998-11-02 2004-07-27 Авентис Фарма Лимитед Замещенные анилиды, фармацевтическая композиция и способ лечения
JP3750494B2 (ja) 1999-08-31 2006-03-01 松下電器産業株式会社 半導体装置
WO2006093991A1 (fr) * 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Composes se liant a l'antigene membranaire specifique de la prostate (psma) et utilisations associees
EP2097111B1 (fr) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Hétérodimères d'acide glutamique
ES2700234T3 (es) * 2007-06-26 2019-02-14 Univ Johns Hopkins Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
EP2436376B1 (fr) * 2007-09-28 2014-07-09 BIND Therapeutics, Inc. Ciblage de cellules de cancer utilisant des nanoparticules
PT2318366T (pt) * 2008-08-01 2017-08-02 Univ Johns Hopkins Agentes de ligação a psma e suas utilizações
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
DK3481804T3 (da) * 2016-06-10 2025-01-13 Univ Johns Hopkins Forbedret syntese af radioaktivt mærket hæmmer af prostataspecifikt membranantigen (PSMA) [18F]DCFPyL

Also Published As

Publication number Publication date
ES2914593T3 (es) 2022-06-14
CA2732632C (fr) 2018-01-09
KR20110038725A (ko) 2011-04-14
WO2010014933A2 (fr) 2010-02-04
CN102171187A (zh) 2011-08-31
EP3222615A1 (fr) 2017-09-27
HUE034027T2 (en) 2018-01-29
JP7219497B2 (ja) 2023-02-08
JP7277113B2 (ja) 2023-05-18
JP6524046B2 (ja) 2019-06-05
NO2024006I1 (no) 2024-02-01
CA2732632A1 (fr) 2010-02-04
RU2011107752A (ru) 2012-09-10
WO2010014933A3 (fr) 2010-05-20
US20180236110A1 (en) 2018-08-23
LT2318366T (lt) 2017-10-25
EP2318366A4 (fr) 2011-12-14
RU2494096C2 (ru) 2013-09-27
US20140369931A1 (en) 2014-12-18
JP2017048204A (ja) 2017-03-09
CN107382846A (zh) 2017-11-24
SI3222615T1 (sl) 2022-11-30
HUE059436T2 (hu) 2022-11-28
FR23C1044I2 (fr) 2024-08-23
JP6030724B2 (ja) 2016-11-24
CY2023024I2 (el) 2024-12-13
JP2015007058A (ja) 2015-01-15
US20110142760A1 (en) 2011-06-16
CN107382846B (zh) 2021-07-06
HRP20220742T1 (hr) 2022-10-28
AU2009276423A1 (en) 2010-02-04
US20220088229A1 (en) 2022-03-24
US20200282083A1 (en) 2020-09-10
NL301250I2 (nl) 2023-11-23
JP2016053025A (ja) 2016-04-14
ES2634894T3 (es) 2017-09-29
FR23C1044I1 (fr) 2023-12-29
PT2318366T (pt) 2017-08-02
JP5806765B2 (ja) 2015-11-10
US9861713B2 (en) 2018-01-09
DK3222615T3 (da) 2022-06-20
CY2023024I1 (el) 2024-02-16
US8778305B2 (en) 2014-07-15
CA2987744A1 (fr) 2010-02-04
CY1119367T1 (el) 2018-02-14
HK1247197A1 (zh) 2018-09-21
EP2318366B1 (fr) 2017-05-03
US20250177578A1 (en) 2025-06-05
SI2318366T1 (sl) 2017-10-30
AU2009276423B2 (en) 2014-10-30
EP4089074A1 (fr) 2022-11-16
HRP20171133T1 (hr) 2017-10-20
JP2021095407A (ja) 2021-06-24
US20160114060A1 (en) 2016-04-28
PL3222615T3 (pl) 2022-09-26
PL2318366T3 (pl) 2017-10-31
CY1125468T1 (el) 2025-05-09
EP2318366A2 (fr) 2011-05-11
CN102171187B (zh) 2017-07-28
LTPA2023534I1 (fr) 2023-12-11
US9226981B2 (en) 2016-01-05
JP2019055973A (ja) 2019-04-11
US10500292B2 (en) 2019-12-10
DK2318366T3 (en) 2017-08-21
HUS2300039I1 (hu) 2023-12-28
PT3222615T (pt) 2022-06-20
LTC2318366I2 (fr) 2025-08-25
US12070513B2 (en) 2024-08-27
JP2011529919A (ja) 2011-12-15
LT3222615T (lt) 2022-08-25
JP5588441B2 (ja) 2014-09-10
KR101664855B1 (ko) 2016-10-11
FIC20230033I1 (fi) 2023-11-02
SMT201700371T1 (it) 2017-09-07
CN113563262A (zh) 2021-10-29
CA2987744C (fr) 2022-11-15
EP3222615B1 (fr) 2022-05-04

Similar Documents

Publication Publication Date Title
BR112016019572A2 (fr)
BRPI0909040A2 (fr)
BRPI0908549B8 (fr)
BRPI0907698A2 (fr)
BRPI0922455A2 (fr)
BRPI0923734A2 (fr)
BRPI0922669A2 (fr)
BRPI0908285A2 (fr)
BRPI0914750A2 (fr)
BRPI0910485A2 (fr)
BRPI0908120A2 (fr)
BRPI0920914A2 (fr)
BRPI0922550A2 (fr)
BRPI0913605A2 (fr)
BRPI0909508A2 (fr)
BRPI0910572A2 (fr)
CH2352018H2 (fr)
BRPI0919477A2 (fr)
AR073287B1 (fr)
BRPI0923127A (fr)
BRPI0923137A2 (fr)
CL47313B1 (fr)
BRMU8803485U8 (fr)
CN300880503S (zh) 咖啡壶
CN300889331S (zh) 电子薄膜按钮(圆形双触点c)